TG Therapeutics announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has issued a positive opinion recommending the approval of BRIUMVI for the treatment of adult patients relapsing forms of multiple sclerosis, RMS, with active disease defined by clinical or imaging features. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, "The positive recommendation to approve BRIUMVI by the CHMP takes us one step closer to delivering BRIUMVI to patients and healthcare providers in Europe. Following today’s recommendation, we look forward to hearing a decision on the marketing authorization application by the European Commission in the coming months."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TGTX:
- TG Therapeutics Announces Positive CHMP Opinion for BRIUMVI™ (ublituximab-xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults
- JPMorgan views TG Therapeutics as undervalued after survey
- TG Therapeutics management to meet with B. Riley
- TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting
- TG Therapeutics reports Q4 EPS (39c), consensus (26c)